Characteristics of class A G protein-coupled receptor crystal structures
Structure | Release Year | PDB ID | Resolution/Space Group | Mutations | Truncations | Unresolved Residues | Ligands/complexes or fusions/other alternations |
|---|---|---|---|---|---|---|---|
| Bovine rhodopsin | 2000 | 1f88 | 2.80 Å/P41 | Gln236-Glu239, Leu328-Ala333 | 11-cis-Retinal | ||
| Bovine rhodopsina | 2003 | 1gzm | 2.65 Å/P31 | Pro327-Gly329, Ala333-Ala348 | 11-cis-Retinal | ||
| Bovine rhodopsin | 2004 | 1u19 | 2.20 Å/P41 | 11-cis-Retinal | |||
| 9-cis-Bovine rhodopsin (isorhodopsin) | 2007 | 2ped | 2.95 Å/P41 | 9-cis-Retinal | |||
| Recombinant bovine rhodopsin mutant | 2007 | 2j4y | 3.40 Å/P31 | N2C, D282C | Leu328-Ala348 | 11-cis-Retinal | |
| Squid rhodopsin | 2008 | 2z73 | 2.50 Å/P62 | Ser359-Ala448 | Met1-Asn8 | 11-cis-Retinal | |
| Squid rhodopsin | 2008 | 2ziy | 3.70 Å/C 2 2 21 | V18I | Met374-Ala448 | Gly2-Arg3 | 11-cis-Retinal |
| Bovine bathorhodopsin | 2006 | 2g87 | 2.60 Å/P41 | all-trans-Retinal | |||
| Bovine lumirhodopsin | 2006 | 2hpy | 2.80 Å/P41 | all-trans-Retinal | |||
| Bovine meta II-like rhodopsin (photoactivated) | 2006 | 2i37 | 4.15 Å/P3112 | Val230-Gln238, Lys311-Phe313, Asp330-Ala348 | all-trans-Retinal | ||
| Opsin | 2008 | 3cap | 2.90 Å/H3 | Pro327-Ala348 | |||
| Opsin | 2008 | 3dqb | 3.20 Å/H 3 2 | K341L | Pro327-Ala348 | C-terminal peptide (11 mer) derived from the Gα subunit of transducin | |
| Turkey β1-Adrenergic receptor | 2008 | 2vt4 | 2.70 Å/P1 | R68S, M90V, C116L, Y227A, A282L, F327A, F338M, C358A, and deglycosylated | Asp2-Ser32, Cys244-Arg271, Ala368-Ala496 | Met1-Gly2, Ala33-Gln39, Arg239-Arg243, Ala272-Met283, Pro360-Leu367 | Cyanopindolol |
| Human β2-adrenergic receptor | 2007 | 2r4r | 3.40 Å/C 2 (C 121) | Tyr366-Leu413 | Met1-Met336, Lys60, Ala91-Glu107, Ser165-Ala202, Gln243-Lys263, Val292-Leu310, Ala349-Gly365 | Carazolol; Fab attachment to C-III loop and portion of helix VII | |
| Human β2-adrenergic receptor | 2007 | 2rh1 | 2.40 Å/C 2 (C 121) | N187E (elimination of glycosylation site), Gln231-Ser262 (replaced by amino acids 2-161 of T4 lysozyme), C1054T and C1097A (lysozyme) | Tyr366-Leu413 | Met1-Arg28, Arg343-Gly365 | Carazolol; T4 lysozyme chimera to C-III loop |
| Human β2-adrenergic receptor | 2008 | 3d4s | 2.80 Å/P212121 | E122W, N187E (elimination of glycosylation site), Gln231-Ser262 (replaced by amino acids 2-161of T4 lysozyme), C1054T and C1097A (lysozyme) | Arg349-Leu413 | Met1-Val31, Arg343-Lys348 | Timolol; T4 lysozyme chimera to C-III loop |
| Human A2A adenosine receptor | 2008 | 3eml | 2.60 Å/P1 21 1 | Leu209-Ala221 (replaced by amino 2-161 acids of T4 lysozyme), C1054T and C1097A (lysozyme) | Ala317-Ser412 | Met1-Pro2, Gln148-Ser156, Gln311-Ala316 | ZM241385 antagonist; T4 lysozyme chimera to C-III loop |